Task A4 · direct factual retrieval
According to the corpus, which signaling pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer, and what investigational drug for this target is described being trialed?
Gold evidence
Acceptable answer concepts
- PI3K-AKT pathway
- PIK3CA mutations
- Inavolisib
Construction note
Directly from PMID:42701058's abstract: the PI3K-AKT pathway description, PIK3CA mutation prevalence in endometrial cancer, and the trialed drug Inavolisib (title and abstract).
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 657 tokens · 5.0sBased on general biomedical knowledge, the PI3K/AKT/mTOR signaling pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer. Investigational drugs targeting this pathway include alpelisib (a PI3K inhibitor) and everolimus (an mTOR inhibitor), which are being trialed for such cancers.
The PI3K/AKT/mTOR signaling pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer.
Alpelisib is an investigational drug targeting the PI3K pathway and is being trialed for PIK3CA-mutated endometrial cancer.
Everolimus is an investigational drug targeting the mTOR pathway and is being trialed for PIK3CA-mutated endometrial cancer.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2874 tokens · 5.7sThe phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer, and the investigational drug inavolisib is described being trialed.
The phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer.
The investigational drug inavolisib is described being trialed for PIK3CA-mutated endometrial cancer.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 2966 tokens · 8.7sThe phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer, and the investigational drug inavolisib is described being trialed for this target.
The phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer.
The investigational drug inavolisib is described being trialed for the treatment of PIK3CA-mutated endometrial cancer.